Dr. Ji Hyun Kim, MD

Dr. Kim practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Kim's NPI, 1558523217, was assigned on June 25, 2008. Dr. Kim graduated from Drexel University College Of Medicine in 2008. Dr. Kim holds California license A111884.

Dr. Kim's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Kim's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. Dr. Kim is also affiliated with Providence Little Company of Mary Medical Center Torrance. The medical group on file is City of Hope. Dmand AI also links Dr. Kim to 1 more group practice or clinic, 1 other site and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kim practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Kim's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Kim is board certified in radiation oncology by the American Board of Radiology. Dr. Kim is licensed in California.

Dmand AI lists anal cancer radiation, bone cancer radiation, brain cancer radiation, breast cancer radiation, cervical cancer radiation, colorectal cancer radiation, head & neck cancer radiation and lung cancer radiation among the conditions Dr. Kim treats.

CMS data shows 2,260 Medicare services from Dr. Kim across 18 procedure codes in 2024, for 186 Medicare patients. Medicare paid $434,469 for them. Every service was in an office.

CMS counts 186 Medicare patients who saw Dr. Kim in 2024. The largest group is 65 to 74, with 80 patients. 75% of them have cancer, and 75% have high blood pressure. 27% are also on Medicaid. Their average risk score is 1.91, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kim's median patient age at 69, with 64% women.

In 2024, Dr. Kim wrote 106 Medicare Part D claims for 43 patients. 90% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $165 in total drug cost. In 2022, CMS named 15 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Kim for performance year 2024, reported as part of a group. Dr. Kim accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kim as offering telehealth.

Dmand AI links 14 papers to Dr. Kim, published from 2012 to 2023. 2019 was the busiest year, with 3. The most frequent topics are Magnetic Resonance Imaging, Stroke and Thalamus. Dr. Kim has published most often in Sleep Med. Dr. Kim's most frequent co-authors are Steven C. Cohen, MD, Stephen J. Forman, MD and Paul Matthew Mandelin, DO.

Dmand AI links Dr. Kim to 3 clinical trials, 3 of them phase 3 studies. 3 are still active or recruiting. Conditions studied include Brain Neoplasms, Breast Neoplasms and Breast Diseases. Canadian Cancer Trials Group sponsors the most, 2.

CMS Open Payments shows 9 general payments to Dr. Kim from 7 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. Medtronic USA, Inc. paid the most, $113.

Dr. Kim graduated from Drexel University College Of Medicine in 2008.

Dr. Kim is in network with 9 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.